tirzepatide glp gip Effects of tirzepatide, a dual and GLP-1 receptor agonist, on blood pressure, cardiac function, and sympathetic nervous system in stroke-prone spontaneously hypertensive rats Tirzepatide is a first-in-class dual

Both approaches are safe

Vildagliptin: peripheral oedema and nasopharyngitis Interactions Clinically significant drug interactions are described as follows: *Sitagliptin is metabolised primarily by CYP3A4, in severe renal impairment metabolism plays a more significant role in sitagliptin elimination, therefore potent CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin) may increase sitagliptin plasma levels in severe renal impairment The blood glucose-lowering effects of DPP-4 inhibitors may also be enhanced or inhibited by other substances: References DPP-4 inhibitors | Prescribing information | Diabetes type 2 | CKS | NICE Sitagliptin 100 mg Film-coated Tablets Summary of Product Characteristics (SmPC) (emc) Onglyza 2.5mg film-coated tablets Summary of Product Characteristics (SmPC) (emc) Trajenta 5 mg film-coated tablets Summary of Product Characteristics (SmPC) (emc) Alogliptin 12.5 mg film-coated tablets Summary of Product Characteristics (SmPC) (emc)

It is not a medicinal product, is not for human or veterinary consumption, and is not intended to diagnose, treat, cure or prevent any disease

Slowed Digestion: Keeps you satisfied longer and naturally helps with portion control

Mounjaro Dosing Progression Weeks 1-4: 2.5 mg weekly (starter dose) Weeks 5-8: 5 mg weekly Weeks 9-12: 7.5 mg weekly Weeks 13-16: 10 mg weekly Weeks 17-20: 12.5 mg weekly Weeks 21+: 15 mg weekly (maximum dose) Mounjaros titration schedule is longer and involves more dose steps